Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $192.31, with a market capitalization of 28.39B. The stock trades at a price-to-earnings (P/E) ratio of 21.95.
During the trading session on 2026-05-14, Biogen(BIIB) shares reached a daily high of $226.00 and a low of $192.00. At a current price of $192.31, the stock is +0.2% higher than the low and still -14.9% under the high.
Trading volume for Biogen(BIIB) stock has reached 1.94M, versus its average volume of 1.01M.
The stock's 52-week range extends from a low of $119.18 to a high of $226.00.
The stock's 52-week range extends from a low of $119.18 to a high of $226.00.
BIIB News
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decision...
Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday...
The company said the CELIA study marked the first randomized Phase 2 trial of a tau-directed therapy to show both biomarker impact and signs of cognitive benefi...
Analyst ratings
53%
of 38 ratingsMore BIIB News
Biogen (BIIB) announced the successful completion of the acquisition of Apellis Pharmaceuticals (APLS). Apellis is now a wholly owned subsidiary of Biogen. In c...
Biogen (BIIB) announced “compelling” topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy ta...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Analyst Jason Zemansky from Bank of America Securities reiterated a Hold rating on Biogen and keeping the price target at $203.00. Unlock hedge fund-level data...
Advertisement Why Biogen (BIIB) is on investors’ radar today Biogen (BIIB) has drawn fresh attention after recent share price moves, with the stock up about 9...
• Biogen stock is showing upward movement. What’s driving BIIB shares up? Biogen Leqembi Iqlik FDA Review Update The FDA has extended the review period for Bi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.